Andere talen Sino Biopharmaceutical Limited

Aandelen

1177

KYG8167W1380

Farmaceutische producten

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:15 12-06-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5,690 ^HKD	+19,29%		+23,16%	+77,81%

10/06	Sino Biopharmaceutical geeft update over fase III-registratieonderzoek naar TQB2868-injectie	RE
09/06	Sino Biopharmaceutical meldt dat Tqc3721 inhalatiesuspensie is goedgekeurd door het Centrum voor Geneesmiddelenbeoordeling	RE

Andere talen

Sino Biopharmaceutical Updates On Phase III Registrational Clinical Study Of TQB2868 Injection	10/06
Sino Biopharmaceutical Says Tqc3721 Inhalation Suspension Approved By Center For Drug Evaluation	09/06
Sino Biopharmaceutical Limited Presents Latest Results of the Phase III Clinical Study for Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Maintenance Treatment for Non-Small Cell Lung Cancer	05/06
Sino Biopharm Presents Lung Cancer Drug Trial Data at US Oncology Conference	05/06
Sino Biopharmaceutical Limited Presents Latest Results of the Phase III Clinical Study for Benmelstobart in Combination with Anlotinib Hydrochloride Capsules	03/06
Sino Biopharm Presents Lung Cancer Study Data at American Oncology Conference	03/06
Sino Biopharm Presents Cancer Drug Data at Oncology Conference	28/05
Sino Biopharmaceutical Limited Presents the Preliminary Data from the First-In-Human Phase I Clinical Study for TQB2102	27/05
Sino Biopharmaceutical Presents Lung Cancer Drug Trial Data at US Oncology Society Meeting	23/05
Sino Biopharmaceutical Limited Announces Data from Phase III Study of Benmelstobart in Combination with Anlotinib for First-Line Treatment of Sq-NSCLC	23/05
Sino Biopharmaceutical Gets FDA Nod to Market Cancer Drug	25/04
Sino Biopharmaceutical Limited Announces Approval for Marketing of Penpulimab Injection by the US FDA	25/04
Sino Biopharmaceutical Gets China Nod for Hematologic Tumor Drug Trial	10/04
Sino Biopharmaceutical Says Tqb3019 (Btk Protac) Approved For Clinical Trial By NMPA	09/04
Biopharmaceutical Limited Announces Application for Clinical Trial of "TQB3019 (BTK PROTAC)" Approved by NMPA	09/04
Sino Biopharmaceutical's Anti-Tumor Drug Gets Implied Approval from China	04/04
Sino Biopharmaceutical Limited Announces Approval for Clinical Trial of TQB2101 (RR1 ADC)	03/04
Sino Biopharmaceutical Says Positive Results On Phase 3 Study Of Culmerciclib In Combination With Fulvestrant	24/03
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Culmerciclib in Combination with Fulvestrant for First-Line Treatment of H-Positive and HER2-Negative Breast Cancer	24/03
Sino Biopharmaceutical's 2024 Attributable Profit Jumps 50%	20/03
Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2024, Payable on 10 July 2025	20/03
Sino Biopharmaceutical Recommends Payment Of Final Dividend Of HK4 Cents Per Share	20/03
Sino Biopharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2024	20/03
Sino Biopharmaceutical's Drug Study Shows 85.2% Failure-Free Survival Rate for 12 Months	11/03
Sino Biopharmaceutical Limited Announces Publication of Results from Phase Ib/IIa Clinical Study of "Rovadicitinib"	10/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Sino Biopharm CEO Eric Tse over vooruitzichten, Aziatische farmaceutische markt & Trump

23 januari 2025 om 14:41 uur